Barclays PLC Myriad Genetics Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Barclays PLC holds 190,243 shares of MYGN stock, worth $2.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

190,243

Previous 190,243 -0.0%

Holding current value

$2.38 Million

Previous $5.21 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$23.97 - $28.6 $2.64 Million - $3.14 Million	109,931 Added 136.88%	190,243 $5.21 Million
Q2 2024 Aug 14, 2024	SELL	$17.98 - $25.47 $1.16 Million - $1.65 Million	-64,767 Reduced 44.64%	80,312 $1.96 Million
Q1 2024 May 15, 2024	SELL	$17.59 - $23.59 $951,900 - $1.28 Million	-54,116 Reduced 27.17%	145,079 $3.09 Million
Q4 2023 Feb 15, 2024	BUY	$13.91 - $21.32 $790,407 - $1.21 Million	56,823 Added 39.91%	199,195 $3.81 Million
Q3 2023 Nov 07, 2023	BUY	$15.99 - $23.22 $208,957 - $303,438	13,068 Added 10.11%	142,372 $2.28 Million
Q2 2023 Aug 03, 2023	BUY	$17.56 - $23.76 $435,382 - $589,105	24,794 Added 23.72%	129,304 $3 Million
Q1 2023 May 04, 2023	SELL	$15.26 - $23.75 $563,658 - $877,253	-36,937 Reduced 26.11%	104,510 $2.43 Million
Q4 2022 Feb 13, 2023	BUY	$14.51 - $20.99 $104,515 - $151,190	7,203 Added 5.37%	141,447 $2.05 Million
Q3 2022 Nov 03, 2022	BUY	$18.21 - $27.88 $1.83 Million - $2.8 Million	100,291 Added 295.38%	134,244 $2.56 Million
Q2 2022 Aug 12, 2022	SELL	$16.45 - $25.88 $609,669 - $959,164	-37,062 Reduced 52.19%	33,953 $617,000
Q1 2022 May 16, 2022	SELL	$22.67 - $28.01 $967,963 - $1.2 Million	-42,698 Reduced 37.55%	71,015 $1.79 Million
Q4 2021 Feb 14, 2022	BUY	$24.13 - $32.63 $272,403 - $368,360	11,289 Added 11.02%	113,713 $3.14 Million
Q3 2021 Nov 09, 2021	BUY	$29.97 - $36.66 $1.69 Million - $2.07 Million	56,376 Added 122.43%	102,424 $3.31 Million
Q2 2021 Aug 13, 2021	SELL	$25.39 - $32.61 $1.2 Million - $1.55 Million	-47,437 Reduced 50.74%	46,048 $1.41 Million
Q1 2021 May 13, 2021	BUY	$19.92 - $31.6 $145,316 - $230,522	7,295 Added 8.46%	93,485 $2.85 Million
Q4 2020 Feb 11, 2021	SELL	$12.16 - $19.77 $831,756 - $1.35 Million	-68,401 Reduced 44.25%	86,190 $1.7 Million
Q3 2020 Nov 12, 2020	BUY	$11.25 - $14.75 $938,722 - $1.23 Million	83,442 Added 117.28%	154,591 $2.02 Million
Q2 2020 Aug 12, 2020	SELL	$10.69 - $16.49 $1.35 Million - $2.08 Million	-125,948 Reduced 63.9%	71,149 $807,000
Q1 2020 May 13, 2020	SELL	$9.78 - $29.53 $1.98 Million - $5.97 Million	-202,150 Reduced 50.63%	197,097 $2.82 Million
Q4 2019 Feb 10, 2020	BUY	$20.93 - $35.1 $6.84 Million - $11.5 Million	326,653 Added 449.97%	399,247 $10.9 Million
Q3 2019 Nov 14, 2019	SELL	$22.08 - $47.08 $994,946 - $2.12 Million	-45,061 Reduced 38.3%	72,594 $2.08 Million
Q2 2019 Aug 14, 2019	BUY	$22.67 - $35.0 $1.58 Million - $2.45 Million	69,909 Added 146.42%	117,655 $3.27 Million
Q1 2019 May 15, 2019	BUY	$26.93 - $34.7 $483,474 - $622,969	17,953 Added 60.26%	47,746 $1.59 Million
Q4 2018 Feb 14, 2019	SELL	$27.23 - $45.56 $1.88 Million - $3.15 Million	-69,048 Reduced 69.86%	29,793 $866,000
Q3 2018 Nov 14, 2018	BUY	$37.57 - $50.34 $2.35 Million - $3.15 Million	62,660 Added 173.18%	98,841 $4.55 Million
Q2 2018 Aug 14, 2018	SELL	$27.75 - $40.17 $1.26 Million - $1.82 Million	-45,427 Reduced 55.66%	36,181 $1.35 Million
Q1 2018 May 15, 2018	BUY	$28.83 - $41.01 $469,006 - $667,150	16,268 Added 24.9%	81,608 $2.41 Million
Q4 2017 Feb 14, 2018	SELL	$28.45 - $37.14 $704,621 - $919,846	-24,767 Reduced 27.49%	65,340 $2.24 Million
Q3 2017 Nov 14, 2017	BUY	$24.01 - $36.2 $2.16 Million - $3.26 Million	90,107	90,107 $3.26 Million

Others Institutions Holding MYGN

# of Institutions

250

Shares Held

90.6M

Call Options Held

100K

Put Options Held

34K

View Full List

About MYRIAD GENETICS INC

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.01B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

More about MYGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account